NYSE American · Biotechnology · USD
MAIA Biotechnology, Inc. (MAIA) Stock Analysis
MAIA Biotechnology, Inc. (MAIA) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MAIA Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.13
- Previous Close
- $1.12
- Day's Range
- 1.06–1.15
- 52-Week Range
- 0.87–3.19
- Volume
- 107.40K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.28
Valuation
- Market Cap
- $70.39M
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 1.03
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.62
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$22.40M
- Shares Outstanding
- 61.74M
- 1-Year Return
- −16.18%
Dividend and dates
- Avg Volume
- 483.76K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MAIA closed at $1.14, −16.18% over 1 year.
MAIA Biotechnology, Inc. (MAIA) has a market capitalization of $70.39M.
In fiscal 2025, MAIA reported revenue of $0.00.
MAIA Stock Return by Calendar Year
MAIA Biotechnology, Inc. (MAIA) return since Jul 2022: what $10,000 became
- 1 year
- $10,000 $8,382
- −16.18%
- 3 years
- $10,000 $4,790
- −52.10%
- Since Jul 2022
- $10,000 $2,556
- −74.44%
If you had invested $10,000 in MAIA Biotechnology, Inc. (MAIA) at the close on July 28, 2022, the earliest close on record here, it would have been worth $2,556 at the close on October 21, 2026: −74.44% in total, −27.55% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −25.49% |
| 2025 | −22.73% |
| 2024 | +69.23% |
| 2023 | −66.67% |
| 2022 (partial year) | −21.30% |
As of October 21, 2026.
MAIA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$22.40M | — |
| 2024 | $0.00 | −$23.25M | — |
| 2023 | $0.00 | −$19.77M | — |
| 2022 | $0.00 | −$15.77M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$23.91M | −$22.40M | — |
| 2024 | $0.00 | — | −$16.88M | −$23.25M | — |
| 2023 | $0.00 | — | −$20.01M | −$19.77M | — |
| 2022 | $0.00 | — | −$15.86M | −$15.77M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
YahooMAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer
BenzingaMAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement
BenzingaMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
YahooMAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
BenzingaMAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Yahoo
All 13 articles ↓Show fewer ↑
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
YahooMAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer
BenzingaMAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
YahooMAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share
BenzingaMAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
YahooMAIA Biotechnology Files $150M Mixed Shelf Offering
BenzingaMAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B